Advancing its strategy to become a leading global biotech Shire plc has acquired Dyax Corp. for approximately $5.9 billion. Dyax is a publicly traded, Massachusetts-based biotechnology company primarily focused on the development of plasma kallikrein (pKal) inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease. Dyax has successfully developed and commercialized Kalbitor, which is approved for HAE acute treatment in patients 12 years of age and ol...